Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

View from the top: expert opinion from leading specialists

The burden of anaemia of chronic kidney disease (CKD) and the general challenges of its management

Here we share the experience of experts in the field on the impact of anaemia of CKD and how poor management can impact patients.

Professor Sunil Bhandari on the challenges of managing anaemia of CKD

Video References:

  • Institute for Health Metrics and Evaluation. Findings from the Global Burden of Diseases Study 2017. Available from: https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf [Last accessed: Nov 2024].
  • Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018;94(3):567–581.
  • Kantar Health. Understanding what it is really to live with anaemia associated CKD. European Presentation: 12 June 2015.
  • Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.
  • Pulignano G, Del Sindaco D, Di Lenardo A, et al. Chronic Renal Dysfunction and Anaemia Are Associated With Cognitive Impairment in Older Patients with Heart Failure. J Cardiovasc Med (Hagerstown) 2014;15:481–490.
  • Tsai SF, Tarng DC. Anemia in patients of diabetic kidney disease. J Chin Med Assoc. 2019 Oct 1;82(10):752-5.
  • Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopathic Medicine and Primary Care. 2007 Dec;1(1):1-1.
  • Amenós AC, López RO, Pérez JM. Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy. Nefrología (English Edition). 2017 Nov 1;37(6):587-91.
  • Mimura I, Tanaka T, Nangaku M. How the target hemoglobin of renal anemia should be?. Nephron. 2015;131(3):202-9.
  • Rossert J, Froissart M, Jacquot C. Anemia management and chronic renal failure progression. Kidney Intl. 2005 Dec 1;68:S76-81.
  • Kazancioglu, R. Risk Factors for chronic kidney disease: an update. Int Soc Nephrol. 2013;3:368-371.

Professor Jonathan Barratt on the disease burden of CKD

Video References:

  • Eriksson D et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17:97.
  • Pulignano G, Del Sindaco D, Di Lenardo A, et al. Chronic Renal Dysfunction and Anaemia Are Associated With Cognitive Impairment in Older Patients with Heart Failure. J Cardiovasc Med (Hagerstown) 2014;15:481–490.
  • Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and End-stage Renal Disease in Patients with Type 2 Diabetes and Nephropathy. Kidney Intl 2004;66:1131–1138.
     

CKD, chronic kidney disease; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase.

Tell Me More

Tell me more

I would like to receive:

*Mandatory fields

*) I hereby consent that Astellas Pharma Nordic** can use the personal details I have provided for the purpose of sending me healthcare, medical and scientific-related information and materials, including invitations*** for Astellas events and activities by email, which Astellas believes may be of value to me, relevant to my work or tailored to my professional profile and may be promotional in nature.

IMPORTANT: Your consent is voluntary and you can withdraw it at any time by clicking the “unsubscribe” link in any email communication you receive from Astellas going forward, by sending an email to privacy@astellas.com.

Astellas is committed to protecting your personal information and will only use it in accordance with the applicable data privacy law and our Astellas Privacy Notice. For further information on how we process and protect your personal information and how you may exercise your data protection rights, please refer to our Privacy Notice at https://policy.astellas.dk/se-privacy-notice-hcp/.

If you have any questions or concerns, please contact us at privacy@astellas.com.

**) For the purpose of this consent, “Astellas Pharma Nordic” shall mean Astellas Pharma a/s (Denmark), Astellas Pharma AB (Sweden), Astellas Pharma (Norway) and Astellas Pharma A/S, filial i Finland (Finland).

***) Astellas complies with applicable industry requirements, and will not send any invitations directly to any hospital-employed HCPs where not allowed.

EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx (särskilt läkemedel), F

▼Detta läkemedel är föremål för utökad övervakning.

Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens tredje trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga (inklusive dödliga) kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Fertila kvinnor måste använda en högeffektiv preventivmetod under behandling och i minst en vecka efter sista dosen. Försiktighet gällande administrering krävs vid måttligt nedsatt leverfunktion och rekommenderas inte vid kraftigt nedsatt leverfunktion. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.

Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2024-09. 

För ytterligare information och förpackningar se www.fass.se.